Allogene Therapeutics, Inc. (ALLO) DCF Valuation

Allogene Therapeutics, Inc. (ALLO) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Allogene Therapeutics, Inc. (ALLO) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Evaluate Allogene Therapeutics, Inc.'s (ALLO) financial outlook like an expert! This (ALLO) DCF Calculator provides pre-filled financial data along with the flexibility to modify revenue growth, WACC, margins, and other essential assumptions to align with your projections.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 38.5 .2 .1 .1 .0 .0 .0 .0
Revenue Growth, % 0 0 0 -99.37 -60.91 -40.07 -40.07 -40.07 -40.07 -40.07
EBITDA -179.9 -250.8 -169.7 -321.2 -300.3 .0 .0 .0 .0 .0
EBITDA, % 100 100 -441 -132197.94 -316097.89 -20 -20 -20 -20 -20
Depreciation 5.0 11.5 10.5 14.3 14.2 .0 .0 .0 .0 .0
Depreciation, % 100 100 27.16 5882.72 14946.32 85.43 85.43 85.43 85.43 85.43
EBIT -184.9 -262.3 -180.2 -335.5 -314.5 .0 .0 .0 .0 .0
EBIT, % 100 100 -468.16 -138080.66 -331044.21 -20 -20 -20 -20 -20
Total Cash 588.9 1,032.1 809.5 576.5 448.7 .1 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .2 .5 .0 .0 .0 .0 .0
Account Receivables 2.4 .0 .0 .0 .0
Account Receivables, % 100 100 0 0 0
Inventories -60.7 -207.0 -20.0 -62.5 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 -52.02 -25700 0 9.6 9.6 9.6 9.6 9.6
Accounts Payable 9.3 10.4 10.3 13.9 5.9 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 26.64 5716.05 6207.37 85.33 85.33 85.33 85.33 85.33
Capital Expenditure -50.8 -66.0 -21.4 -5.2 -1.5 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 -55.72 -2136.21 -1595.79 -51.14 -51.14 -51.14 -51.14 -51.14
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -184.6 -244.8 -171.7 -332.7 -314.5 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -162.8 -149.4 -369.8 -277.5 -372.3 -5.9 .0 .0 .0 .0
WACC, % 7.54 7.48 7.49 7.53 7.54 7.52 7.52 7.52 7.52 7.52
PV UFCF
SUM PV UFCF -5.5
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -5
Net Debt 12
Equity Value -17
Diluted Shares Outstanding, MM 157
Equity Value Per Share -0.11

What You Will Get

  • Genuine Allogene Data: Preloaded financials – encompassing revenue to EBIT – derived from actual and projected figures.
  • Comprehensive Customization: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates.
  • Immediate Valuation Updates: Automatic recalculations to assess the effects of changes on Allogene Therapeutics' fair value.
  • Flexible Excel Template: Designed for quick modifications, scenario analysis, and detailed forecasts.
  • Efficient and Precise: Avoid the hassle of building models from the ground up while ensuring accuracy and adaptability.

Key Features

  • Comprehensive Data: Allogene Therapeutics’ historical financial records and pre-filled projections.
  • Customizable Inputs: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
  • Real-Time Calculations: View Allogene Therapeutics’ intrinsic value update instantly.
  • Visual Analytics: Dashboard graphs illustrate valuation outcomes and essential metrics.
  • Designed for Precision: A reliable tool for analysts, investors, and finance professionals.

How It Works

  1. Download the Template: Gain immediate access to the Excel-based ALLO DCF Calculator.
  2. Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
  3. Instant Calculations: The model automatically recalculates Allogene Therapeutics’ intrinsic value.
  4. Test Scenarios: Experiment with different assumptions to assess potential valuation variations.
  5. Analyze and Decide: Leverage the results to inform your investment or financial analysis.

Why Choose This Calculator for Allogene Therapeutics, Inc. (ALLO)?

  • Accurate Data: Up-to-date Allogene financials provide trustworthy valuation outcomes.
  • Customizable: Tailor essential metrics like growth rates, WACC, and tax rates to fit your forecasts.
  • Time-Saving: Ready-to-use calculations save you from starting from the ground up.
  • Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotech sector.
  • User-Friendly: Easy-to-navigate design and clear instructions ensure accessibility for all users.

Who Should Use Allogene Therapeutics, Inc. (ALLO)?

  • Healthcare Investors: Make informed decisions with a cutting-edge biotechnology investment tool.
  • Biotech Analysts: Streamline your analysis with a customizable model tailored for gene therapy insights.
  • Consultants: Effortlessly modify the template for client discussions or strategic reports.
  • Life Sciences Enthusiasts: Enhance your knowledge of innovative therapies using real-world case studies.
  • Educators and Students: Utilize it as a hands-on resource in courses focused on biotechnology and healthcare.

What the Template Contains

  • Operating and Balance Sheet Data: Pre-filled Allogene Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
  • WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
  • DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
  • Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
  • Key Ratios: Includes profitability, leverage, and efficiency ratios for Allogene Therapeutics, Inc. (ALLO).
  • Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.

No products were found matching.